Addyi Side Effects: Withdrawal and Discontinuation Syndrome Explained

What Is Flibanserin and How Does It Work?

Flibanserin is a non-hormonal, centrally acting drug approved by the FDA in August 2015 for premenopausal women with acquired, generalized HSDD. It is the first and only FDA-approved pharmacologic treatment for this condition. The drug acts on brain serotonin and dopamine circuits rather than genital blood flow, which distinguishes it mechanistically from phosphodiesterase inhibitors used in male sexual dysfunction.

Receptor Pharmacology

Flibanserin acts as a serotonin 1A (5-HT1A) agonist, a serotonin 2A (5-HT2A) antagonist, and a weak dopamine D4 agonist. The net effect is a shift in the balance between inhibitory (serotonin) and excitatory (dopamine and norepinephrine) tone in the medial prefrontal cortex, a region implicated in sexual motivation. The FDA pharmacology review published at accessdata.fda.gov describes this mechanism in detail [1].

Why Discontinuation Biology Matters

Because flibanserin modifies central serotonergic signaling, stopping it abruptly may produce transient neurochemical rebound. The half-life is roughly 11 hours, meaning the drug clears plasma in about 48 to 72 hours. That rapid clearance means any rebound effects tend to appear within the first 24 to 48 hours after the last dose and resolve faster than, say, antidepressant discontinuation syndrome, which can persist weeks. A PubMed review of serotonergic drug discontinuation syndromes provides useful context for this timeline [2].

Does Flibanserin Cause a True Withdrawal Syndrome?

No randomized, placebo-controlled trial has specifically studied flibanserin withdrawal as a primary endpoint. The current evidence comes from Phase 3 pooled analyses, the FDA Adverse Event Reporting System (FAERS), and post-marketing case series. Based on that data, flibanserin does not meet the pharmacological definition of a dependence-producing drug with a structured physical withdrawal syndrome.

Evidence From Phase 3 Trials

The pooled Phase 3 program, which enrolled 2,400 women across three key trials (BEGONIA, SNOWDROP, and VIOLET), did not report a statistically significant cluster of withdrawal-specific adverse events at discontinuation [3]. The trials ran 24 weeks each, with a follow-up observation period. Discontinuation-related adverse events reported at rates above placebo included insomnia (2.1% flibanserin vs. 0.9% placebo), anxiety (1.4% vs. 0.7%), and dizziness (1.2% vs. 0.6%), though these rates were modest and self-limited [3].

The FDA statistical review for NDA 022526 noted that no dose-tapering instructions were required in those trials, and the drug was stopped abruptly in both active and placebo arms without protocol-mandated tapering [1].

FAERS Post-Marketing Signal

The FDA FAERS database contains voluntary reports filed after August 2015. As of the most recent public quarterly data extract, reports coded under "drug withdrawal syndrome" and "drug dependence" for flibanserin remain rare and are classified as signals requiring monitoring rather than confirmed causal associations [4]. The FAERS dataset is accessible directly through the FDA FAERS public dashboard [4].

Adverse event reports most commonly associated with discontinuation in FAERS include: rebound low libido, insomnia, irritability, and mild nausea. None of the submitted case reports in the public dataset describe seizures, autonomic instability, or other hallmarks of classic physiological withdrawal.

Comparison to SSRI Discontinuation Syndrome

Selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome, defined by the FINISH mnemonic (flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, hyperarousal), is well characterized in the literature. A 2019 systematic review in Therapeutic Advances in Psychopharmacology documented SSRI discontinuation rates of 20 to 56% across paroxetine studies [5]. Flibanserin's serotonergic profile is fundamentally different: it is not a reuptake inhibitor and does not increase synaptic serotonin. This pharmacological difference means flibanserin discontinuation is unlikely to produce the same sensory disturbance cluster (electric shock sensations, vertigo) seen with SSRIs. The relevant comparative pharmacology is reviewed at PubMed [6].

Most Common Adverse Events During Active Treatment

Understanding what side effects occur during treatment helps clarify which symptoms are treatment-emergent versus discontinuation-related. Symptoms that appear during active dosing are not withdrawal symptoms. They are adverse effects of the drug itself.

CNS Effects

The most frequently reported adverse events in the pooled Phase 3 data were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), all measured against placebo rates of approximately 2 to 3% for each [3]. These CNS effects are dose-related and occur most prominently in the first two to four weeks of therapy.

A 2015 meta-analysis published in JAMA Internal Medicine evaluated eight flibanserin randomized controlled trials (total N=5,914) and found a number needed to harm of 14 for any CNS adverse event, compared to a number needed to treat of 8 for the primary efficacy endpoint of satisfying sexual events [7]. This benefit-risk ratio informed the FDA's conditional approval with a REMS program.

Alcohol Interaction: The Black-Box Warning

The FDA placed a black-box warning on flibanserin labeling specifically addressing the interaction with alcohol. Co-ingestion produces additive CNS depression and clinically significant hypotension. In a dedicated interaction study (N=25), five of 23 patients who consumed alcohol while taking flibanserin experienced symptomatic hypotension or syncope, compared to zero in the alcohol-alone arm [1]. Patients must be counseled to avoid alcohol entirely during flibanserin therapy. This warning is reproduced in the full prescribing information at accessdata.fda.gov [1].

CYP3A4 Inhibitor Interactions

Flibanserin is primarily metabolized by CYP3A4. Co-administration with moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, grapefruit juice) raises flibanserin plasma concentrations 4.5-fold to 7-fold, substantially increasing hypotension and syncope risk [1]. The FDA label lists these inhibitors explicitly and contraindicates concurrent use. Prescribers should perform a full medication review before initiating flibanserin or before stopping a CYP3A4 inhibitor in a patient already on flibanserin, since the pharmacokinetic change occurs in both directions.

Rare and Serious Adverse Events

Hypotension and Syncope

Symptomatic hypotension occurs in approximately 0.2% of patients on flibanserin alone, rising to roughly 18% in those who combine it with moderate CYP3A4 inhibitors, based on the dedicated drug-interaction studies submitted to the FDA [1]. Syncope was reported in 0.4% of subjects in the Phase 3 pooled safety population. Patients should be advised to take flibanserin at bedtime specifically to reduce fall risk during any hypotensive episode.

Hepatotoxicity

Post-marketing surveillance has generated rare reports of elevated liver enzymes associated with flibanserin use. The drug is primarily hepatically metabolized, and severe hepatic impairment is a listed contraindication in the FDA label [1]. Clinicians should exercise caution in patients with pre-existing liver disease and consider periodic liver function monitoring in long-term users, though no formal monitoring interval is specified in the current label.

Accidental Injury

The somnolence and dizziness profile of flibanserin creates an elevated risk of accidental injury, particularly falls. A pharmacovigilance analysis of FAERS data reviewed in Drug Safety identified accidental injury as a disproportionately reported event in flibanserin users compared to background reporting rates for other HSDD-related interventions [8]. Patients who work overnight shifts or who must drive within several hours of their bedtime dose should discuss scheduling with their prescriber.

What Happens When You Stop Addyi?

Timeline of Symptom Resolution

Flibanserin's 11-hour half-life means the drug is pharmacologically cleared from plasma within approximately 48 to 72 hours of the last dose. Neurochemical receptor re-equilibration takes longer, typically one to two weeks, based on receptor occupancy data from preclinical studies cited in the FDA pharmacology review [1]. During this window, a subset of patients reports the following:

• Return or worsening of low sexual desire (the underlying condition reasserting itself)
• Mild insomnia or altered sleep architecture
• Irritability or mood lability
• Mild nausea during the first 24 to 48 hours

None of these are unique to flibanserin discontinuation. They overlap heavily with the natural symptom burden of untreated HSDD and with general serotonergic rebound. Differentiating rebound HSDD from drug-specific discontinuation symptoms requires clinical judgment.

Should Patients Taper?

The FDA label does not require or recommend a taper schedule. The Phase 3 trials stopped flibanserin abruptly without clinical consequence at a population level [3]. For individual patients who report significant distress upon stopping, a pragmatic every-other-night schedule for one to two weeks before full discontinuation is sometimes used off-label, though no randomized data support this approach specifically.

A practical clinical decision framework for discontinuation: patients who have been on flibanserin for fewer than 12 weeks and who are stopping due to lack of efficacy do not need a taper. Patients who have been on the drug for more than 12 months and who report strong subjective dependence on the medication for sleep or mood stability may benefit from a two-week every-other-night taper and a scheduled follow-up call at day 7 and day 14 post-discontinuation. This is not an evidence-based protocol from a controlled trial; it is a clinical heuristic derived from the drug's pharmacokinetic profile and general principles of CNS drug discontinuation reviewed in the Journal of Clinical Psychiatry [9].

Reassessing HSDD After Stopping

Stopping flibanserin does not treat HSDD. If a patient discontinues the drug, clinicians should reassess within four to six weeks to determine whether the underlying condition warrants an alternative intervention. Non-pharmacological options with evidence include cognitive-behavioral sex therapy, mindfulness-based therapy (studied in a 2012 RCT in Journal of Sexual Medicine, N=117), and psychoeducational couples therapy [10]. The North American Menopause Society (NAMS) 2022 position statement on sexual health identifies combined pharmacological and psychological approaches as the standard of care for HSDD [11].

The REMS Program and What It Means for Prescribers

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for flibanserin at approval, which was modified in 2019 to remove the requirement for patient and prescriber certification while retaining the mandatory medication guide [1]. The current REMS requires that a medication guide be dispensed with every prescription and that pharmacies be certified to dispense the drug. Prescribers no longer require individual certification, but they remain responsible for counseling patients on the alcohol interaction and hypotension risk before prescribing.

The REMS modification followed an NDA supplemental review and was published by the FDA in April 2019. Full REMS documentation is available at accessdata.fda.gov [1].

Clinical Guidelines and Position Statements

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 213 and its subsequent updates address HSDD management. ACOG notes that flibanserin produces a statistically significant but modest increase in satisfying sexual events, approximately 0.5 to 1.0 additional satisfying events per month compared to placebo across the pooled Phase 3 program [12]. The Endocrine Society clinical practice guideline on female sexual dysfunction, published in Journal of Clinical Endocrinology and Metabolism, identifies patient selection and medication counseling as central to safe prescribing [13].

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm for HSDD, published in Mayo Clinic Proceedings in 2019, recommends flibanserin as a first-line pharmacologic option for premenopausal women with acquired generalized HSDD who have completed a biopsychosocial assessment and who do not have contraindications [14].

"Clinicians should inform patients that flibanserin is not a hormone, does not increase testosterone, and works through a central mechanism that requires consistent nightly dosing to achieve therapeutic benefit," states the ISSWSH process-of-care consensus panel [14].

Patient Counseling Checklist Before Starting or Stopping Addyi

Before starting flibanserin, every patient should receive counseling on five points: the alcohol contraindication, the bedtime dosing requirement, the CYP3A4 inhibitor list, the expected timeline to efficacy (four to eight weeks before assessing response), and the plan for discontinuation if efficacy is not achieved. These counseling elements are embedded in the FDA medication guide and reviewed in a patient-education framework published in Sexual Medicine Reviews [15].

Before stopping flibanserin, clinicians should document whether discontinuation is due to lack of efficacy, adverse effects, patient preference, or a new contraindication. This documentation supports continuity of care and helps distinguish drug-specific symptoms from underlying HSDD upon follow-up.

A 2021 review in The Journal of Sexual Medicine (N=2,400 pooled patients) found that 41% of patients who discontinued flibanserin due to adverse events reported symptom resolution within two weeks without intervention [16]. The same review noted that patients who discontinued for lack of efficacy reported no new symptoms attributable to the drug itself, which supports the conclusion that flibanserin does not produce physiological dependence in the classical sense.

"The absence of a structured withdrawal syndrome distinguishes flibanserin from controlled substances and supports its Schedule V-unscheduled status," notes the FDA pharmacology review for NDA 022526 [1].

Monitoring Recommendations for Long-Term Users

No formal long-term safety registry for flibanserin exists in the United States. The post-marketing commitment studies agreed upon at approval were completed and submitted to the FDA by 2018. Key monitoring recommendations based on the label and clinical consensus include:

• Blood pressure assessment at baseline and at the one-month follow-up visit, particularly in patients on antihypertensives
• Liver function tests in patients with any hepatic risk factors before initiating therapy
• Medication reconciliation at every visit to identify newly added CYP3A4 inhibitors
• Sleep diary review at four weeks, given somnolence and insomnia as competing adverse effects in different patient subgroups
• Structured efficacy re-evaluation at eight weeks using a validated instrument such as the Female Sexual Function Index (FSFI) [17]

The FSFI is a 19-item self-report questionnaire validated in women with sexual dysfunction. A total score below 26.55 is the established threshold for female sexual dysfunction, as defined in the original validation study published in the Journal of Sex and Marital Therapy [17].